Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Ipratropium bromide, Xylometazoline hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for 2. What you need to know before you use Otrivine Extra Dual Relief Nasal spray 3. How to use Otrivine Extra Dual Relief Nasal spray 4. Possible side effects 5. How to store Otrivine Extra Dual Relief Nasal spray 6. Contents of the pack and other information
1. WHAT OTRIVINE EXTRA DUAL RELIEF NASAL SPRAY IS AND WHAT IT IS USED FOR Otrivine Extra Dual Relief Nasal spray is a combination medicinal product consisting of two different substances (xylometazoline hydrochloride and ipratropium bromide). One of the active ingredients (ipratropium bromide) helps with the runny nose, the other (xylometazoline hydrochloride) has a decongesting effect. Otrivine Extra Dual Relief Nasal spray is used for the treatment of nasal congestion with runny nose (rhinorrhea) in connection with common colds.
E OTRIVINE EXTRA DUAL RELIEF NASAL SPRAY Do not use Otrivine Extra Dual Relief Nasal spray
Other medicines and Otrivine Extra Dual Relief Nasal spray Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. It is particularly important that you mention the following:
OTRIVINE EXTRA DUAL RELIEF NASAL SPRAY Always use this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is: Adults: One puff in each nostril as needed, up to 3 times daily for maximum 7 days. Leave at least 6 hours between two doses. Do not exceed 3 applications daily into each nostril. Do not exceed the stated dose. Use the smallest dose you need to treat your symptoms and use it for the shortest time needed to achieve desired effect. Duration of treatment: Do not use this medicine for more than 7 days. It is recommended that you stop treatment with Otrivine Extra Dual Relief Nasal spray as soon as your symptoms improve, even if this is sooner than 7 days, in order to minimise the risk of adverse reactions. If symptoms get worse or do not improve after 7 days, consult a doctor. If you think the effect of this medicine is too strong or too weak, consult your doctor or pharmacist. Instructions for use:
Prime the pump by pumping 5 times. Once primed the pump will normally remain charged throughout regular daily treatment periods. 1. Clear your nose. 2. Hold the bottle upright with thumb on the actuation button. 3. For a no dripping effect, stay upright and insert the nozzle into the nostril. 4. Press on the button to spray and breathe in gently through the nose at the same time. Repeat this procedure (Steps 2 to 4) in the other nostril. 5. After each use, clean and dry the nozzle. 6. Put the protective cap back on until an audible "click" is heard.
1. Clear nose
2. Thumb on button
3. Insert in nose
4. Press button
5. Clean and dry
6. Replace cap
The effect occurs within 5-15 minutes. Should the spray not be ejected during the full actuation stroke, or if the product has not been used for longer than 7 days, the pump will need to be re-primed with 2 pumps. If the full spray is not administered, the dose should not be repeated. To avoid possible spread of infection, the spray should only be used by one person. Avoid spraying Otrivine Extra Dual Relief Nasal spray in or around the eyes. If this happens thoroughly rinse the eyes with cold water. Your vision may become temporarily blurred and the eye irritated, painful and red. If this happens contact your doctor for advice. Worsening of narrow angle glaucoma may also occur. If you use more Otrivine Extra Dual Relief Nasal spray than you should: If you, or someone else, have taken more medicine than you should, contact your doctor, hospital or emergency room for assessment of the risk. It is advisable to take this leaflet, bottle or pack with you. This is particularly important for children who are more likely to develop adverse events than adults. Symptoms of overdose are severe dizziness, sweating, severely lowered body temperature, headache, slow heartbeat, rapid heartbeat, impaired breathing, coma, convulsion, hypertension (high blood pressure) which may be followed by hypotension (low blood pressure). Other symptoms may be dry mouth, difficulties focusing with the eyes and hallucinations. If you forget to use Otrivine Extra Dual Relief Nasal spray Do not take a double dose to make up a forgotten one. MOCK UP
Like all medicines, this medicine can cause side effects, although not everybody gets them. STOP using Otrivine Extra Dual Relief Nasal spray and seek medical help immediately if you have any of the following:
Otrivine Extra Dual Relief Nasal spray is available as a 10 ml nasal spray with a thumb laterally actuated metered-dose spray pump with protective cap. Market Authorisation Holder Haleon Ireland Dungarvan Limited, Knockbrack, Dungarvan, County Waterford, Ireland. Manufacturer Haleon Germany GmbH, Barthstraße4, 80339 München, Germany or Haleon UK Trading Services Limited, Weybridge, KT13 0NY, U.K This medicinal product is authorised in the Member States of the EEA under the following names: AT
Otrivin Duo 0,5 mg/ml + 0,6 mg/ml Nasenspray, Lösung
BE
Otrivine Duo 0,5mg/ml + 0,6mg/ml solution pour pulvérisation nasale
CY
Otrivin Advance (0,5mg/ml + 0,6mg/ml) nasal spray solution
CZ
Otrivin Duo
DK
Otrivin Comp næsespray, opløsning
EE
Otrivin Total
EL
Otrivin Advance 0,5mg/ml + 0,6mg/ml Ρινικό εκνέφωμα, διάλυμα
ES
Rhinovín Duo 0,5 mg/ml + 0,6 mg/ml solución para pulverización nasal
FI
Otrivin Comp 0,5mg/ml + 0,6mg/ml nenäsumute, liuos
HU
Otrivin Komplex 0,5mg/ml + 0,6mg/ml oldatos orrspray
IE
Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml Nasal Spray
IS
Otrivin Comp 0,5mg/ml + 0,6mg/ml nefúði lausn
IT
RINAZINA DOPPIA AZIONE 0,5 mg/ml + 0,6 mg/ml spray nasale, soluzione
LT
OtriDuo 0,5 mg/0,6 mg/ml nosies purškalas, tirpalas
LU
Otrivine Duo 0,5mg/ml + 0,6mg/ml solution pour pulvérisation nasale
LV
Otrivin Total 0,5 mg/ml + 0,6 mg/ml deguna aerosols, šķīdums
MT
Otrivine Extra Dual Relief 0.5mg/ml + 0.6mg/ml Nasal Spray
NL
Otrivin Duo Xylometazoline hydrochloride & Ipratropium bromide, 0,5/0,6 mg/ml, neusspray, oplossing
NO
Otrivin Comp 0,5mg/ml + 0,6mg/ml nesespray, oppløsning
PL
Otrivin Ipra MAX
PT
Vibrocil ActilongDuo 0.5mg/ml + 0.6mg/ml soluçao para pulverizaçao nasal
RO
Vibrocil Duo 0,5mg/ml + 0,6mg/ml spray nazal, solutie
SE
Otrivin Comp 0,5mg/ml + 0,6 mg/ml nässpray lösning
SI
Otrivin Duo 0,5 mg/0,6 mg v 1 ml pršilo za nos, raztopina
SK
Otrivin Duo
UK (NI)
Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml Nasal Spray
This leaflet was last revised in July 2025 Trade Marks are owned by or licensed to the Haleon group of companies.
OTRIVINE EXTRA DUAL RELIEF NASAL SPRAY Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month. This date applies even if the packaging has been opened. Do not store above 25°C. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Otrivine Extra Dual Relief Nasal spray contains The active substances are xylometazoline hydrochloride and ipratropium bromide. 1 ml contains 0.5 mg xylometazoline hydrochloride and 0.6 mg ipratropium bromide. 1 puff contains 70 micrograms xylometazoline hydrochloride and 84 micrograms ipratropium bromide. The other ingredients are disodium edetate, glycerol (85%), purified water, sodium hydroxide and hydrochloric acid. What Otrivine Extra Dual Relief Nasal spray looks like and contents of the pack Otrivine Extra Dual Relief Nasal spray is a clear solution. The bottle contains approximately 70 puffs.
MOCK UP
Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml nasal spray, solution comes as nasal spray containing 0.5mg/ml / 0.6mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml nasal spray, solution is ipratropium bromide, xylometazoline hydrochloride.
This leaflet reproduces the patient information leaflet approved for Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml nasal spray, solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Symptomatic treatment of nasal congestion and rhinorrhea in connection with common colds.
Posology
Adults: 1 puff in each nostril up to 3 times daily. At least 6 hours should elapse between two doses. Do not exceed 3 applications daily into each nostril.
The treatment duration should not exceed 7 days (see section 4.4).
Do not exceed the stated dose. The lowest dose necessary to achieve efficacy should be used for the shortest duration of treatment.
It is recommended to stop treatment, when the symptoms have diminished, even before the maximum duration of treatment of 7 days, in order to minimize the risk of adverse reactions (see section 4.8).
Paediatric population
Otrivine Extra Dual Relief is not recommended for use in children and adolescents below 18 years of age due to lack of sufficient documentation.
Geriatrics
There is only limited experience of use in patients above 70 years of age.
Method of administration
Vertically actuated pump:
Before the first application, prime the pump by actuating 4 times. Once primed the pump will normally remain charged throughout regular daily treatment periods.
1. Clear the nose.
2. Hold the bottle upright with thumb under base and nozzle between two fingers.
3. Lean forward slightly and insert the nozzle into a nostril.
4. Spray and breathe in gently through the nose at the same time.
5. Repeat this procedure in the other nostril.
6. Clean and dry the nozzle before replacing back the cap right after use.
Should the spray not be ejected during the full actuation stroke, or if the product has not been used for longer than 6 days, the pump will need to be reprimed with 4 actuations as initially performed. If the full spray is not administered, the dose should not be repeated.
Thumb laterally actuated pump:
Before the first use
Prime the pump by actuating 5 times. Once primed the pump will normally remain charged throughout regular daily treatment periods.
Remove the cap.
1. Clear the nose.
2. Hold the bottle upright with thumb on the actuation button.
3. For a no dripping effect, stay upright and insert the nozzle into a nostril.
4. Press on the button to spray and breath in gently through the nose at the same time.
Repeat this procedure (step 2 to 4) in the other nostril.
5. After each use, clean and dry the nozzle.
6. Put the protective cap back on until an audible “click” is heard.
Should the spray not be ejected during the full actuation stroke, or if the product has not been used for longer than 7 days, the pump will need to be re-primed with 2 actuations.
If the full spray is not administered, the dose should not be repeated.
To avoid possible spread of infection, the spray should only be used by one person.
Be careful not to spray in the eyes.
Otrivine Extra Dual Relief should not be given to children under the age of 18 due to lack of sufficient documentation.
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Hypersensitivity to atropine or atropine like substances such as, hyoscyamine and scopolamine.
After surgical operations where dura mater may have been penetrated, e.g. trans-sphenoidal hypophysectomy or other trans-nasal operations.
Glaucoma.
Rhinitis sicca or atrophic rhinitis.
The medicinal product must be used with caution in patients who are sensitive to adrenergic substances, which may give symptoms such as sleeping disturbances, dizziness, tremor, cardiac arrythmias or elevated blood pressure.
The medicinal product must be administered with caution to patients with:
- hypertension, cardiovascular diseases. Patients with long QT syndrome treated with xylometazoline may be at increased risk of serious ventricular arrhythmias
- hyperthyroidism, diabetes mellitus
- hypertrophy of the prostate, stenosis of the bladder bar
- pheochromocytoma
- cystic fibrosis
- monoamine oxidase inhibitor (MAOI) treatment or who have received them in the last two weeks (see section 4.5 Interactions)
- Tri and tetra-cyclic antidepressants treatment or who have received them in the last two weeks (see section 4.5 Interactions)
- Beta 2-agonists treatment (see section 4.5 Interactions)
Caution is recommended in patients predisposed to:
- angle closure glaucoma
- epistaxis (e.g. elderly)
- paralytic ileus
Immediate hypersensitivity including urticaria, angioedema, rash, bronchospasm, pharyngeal oedema and anaphylaxis may occur.
The treatment duration should not exceed 7 days, as chronic treatment with xylometazoline hydrochloride may cause swelling of the nasal mucosa and hypersecretion because of increased sensibility in the cells, “rebound effect” (rhinitis medicamentosa).
Patients should be instructed to avoid spraying Otrivine Extra Dual Relief in or around the eye. If Otrivine Extra Dual Relief gets in contact with the eyes, the following may occur: temporary blurred vision, irritation, pain, red eyes. Aggravation of angle closure glaucoma may also develop.
The patient should be instructed to rinse their eyes with cold water if Otrivine Extra Dual Relief gets in direct contact with the eyes and to contact a doctor if they experience pain in the eyes or blurred vision.
Keep out of the sight and reach of children.
Monoaminoxidase inhibitors (MAO inhibitors) or tri- and tetra-cyclic antidepressants
Concomitant use or use within the last 2 weeks of sympathomimetic preparations may induce severely elevated blood pressure and is therefore not recommended. Sympathomimetic preparations release catecholamine, which results in a major release of noradrenaline which in turn has a vasoconstrictive effect resulting in elevated blood pressure. In critical cases of elevated blood pressure, treatment with Otrivine Extra Dual Relief should be discontinued and the elevated blood pressure treated. (see section 4.4 Warnings and Precautions)
Beta 2-agonists
Concomitant use with ipratropium may cause an increased risk of acute glaucoma in patients with a history of angle closure glaucoma.
There have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, narrow-angle glaucoma and eye pain) when aerosolised ipratropium bromide either alone or in combination with an adrenergic beta 2-agonist, has come into contact with the eyes. (see section 4.4 Warnings and Precautions)
Concomitant administration of other anticholinergic drugs may enhance the anticholinergic effect.
The above interactions have been studied individually for both of the active substances of Otrivine Extra Dual Relief, not in combination.
No formal interaction studies with other substances have been performed.
Pregnancy
There are insufficient data on the use of this product in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see Non-clinical information). It is advisable not to take this product during pregnancy.
Xylometazoline
The available data indicate the potential for xylometazoline to exert a systemic vasoconstrictor effect. In view of its systemic vasoconstrictor effect, it is advisable not to take xylometazoline during pregnancy.
Ipratropium
The clinical safety ipratropium bromide during human pregnancy has not been established. Non-clinic data have demonstrated embryotoxicity following administration of ipratropium bromide to rabbits via inhalation at doses greater than the clinical dose (see Non-clinical information).
Breast-feeding
There are insufficient data to determine if this product is excreted in human breast milk. This product should only be used while breast feeding under medical advice. If the expected benefit to the mother is greater than possible risk to the infant, the lowest effective dose and the duration of treatment should be considered.
Xylometazoline
There is no evidence of any adverse effect on the breast-fed infant. It is unknown if xylometazoline is excreted in breast milk.
Ipratropium
It is not known whether ipratropium bromide is excreted in breast milk.
Fertility
There are insufficient data on the impact of this product on fertility.
Xylometazoline
There are no adequate data for the effects of xylometazoline hydrochloride on fertility and no animal studies are available.
Ipratropium
Non-clinical data have demonstrated no evidence of impaired fertility following oral administration of ipratropium bromide to rats at doses greater than the clinical dose (see Preclinical safety data).
Visual disturbances (including blurred vision and mydriasis), dizziness and fatigue have been reported with Otrivine Extra Dual Relief. Patients should be advised that if affected they should not drive, operate machinery or take part in activities where these symptoms may put themselves or others at risk.
Summary of the safety profile
The most commonly reported adverse reactions are epistaxis occurring in 14.8% and nasal dryness occurring in 11.3% of patients.
Many of the adverse events reported are also symptoms of common cold.
Tabulated list of adverse reactions
The adverse reactions are presented by system organ class and frequency. Frequencies are defined as:
Very common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1000 and <1/100); Rare (≥1/10000 and <1/1000); Very rare (< 1/10,000); Not known (can not be estimated from the available data)
Xylometazoline and Ipratropium
The following adverse reactions for the combination of xylometazoline and ipratropium were reported in two randomised clinical studies and one non-interventional post-marketing study with the product as well as from post-marketing surveillance.
MeDRA SOC
Adverse Reactions
Frequency
Immune system disorders
Hypersensitivity reaction (angioedema, rash, pruritis)
Very rare
Psychiatric disorders
Insomnia
Uncommon
Nervous system disorders
Dysgeusia
Common
Parosmia, Tremor
Uncommon
Eye disorders
Eye irritation, dry eye
Uncommon
Photopsia
Not known
Cardiac disorders
Palpitations, tachycardia
Uncommon
Respiratory, thoracic and mediastinal disorders
Epistaxis
Very common
Nasal congestion, rhinalgia
Common
Nasal ulcer, dysphonia, oropharyngeal pain, sneezing
Uncommon
Rhinorrhea
Rare
Paranasal sinus discomfort
Not known
Gastrointestinal disorder
Dyspepsia
Uncommon
Dysphagia
Not known
General disorders and administration site conditions
Fatigue, discomfort
Uncommon
Chest discomfort, thirst
Not Known
Xylometazoline
The following adverse reactions have been reported in clinical trials and post-marketing surveillance with xylometazoline.
MeDRA SOC
Adverse Reactions
Frequency
Nervous system disorders
Headache
Common
Eye disorders
Visual impairment
Very rare
Respiratory, thoracic and mediastinal disorders
Nasal dryness, nasal discomfort
Common
Epistaxis
Uncommon
Gastrointestinal disorders
Nausea
Common
General disorders and administration site conditions
Application site burn
Common
Ipratropium bromide
The following adverse reactions were identified from data obtained in clinical trials and pharmacovigilance during post approval use of the drug.
MeDRA SOC
Adverse Reactions
Frequency
Immune system disorders
Anaphylactic reaction, hypersensitivity
Not known
Nervous system disorders
Dizziness, headache
Common
Eye disorders
Corneal oedema, conjunctival hyperaemia
Uncommon
Glaucoma, intraocular pressure increased, accommodation disorder, blurred vision, halo vision, mydriasis, eye pain
Not known
Cardiac disorders
Supraventricular tachycardia, palpitations
Uncommon
Atrial fibrillation
Not known
Respiratory, thoracic and mediastinal disorders
Throat irritation, dry throat
Common
Cough
Uncommon
Laryngospasm, pharyngeal oedema
Not known
Gastrointestinal disorders
Dry mouth
Common
Nausea
Uncommon
Skin and subcutaneous tissue disorders
Rash, urticaria pruritis
Not known
Renal and urinary disorders
Urinary retention
Not Known
Description of selected adverse reactions
Several of the adverse reactions listed under “Not known” have only been reported once for the product in clinical trials or are reported from postmarketing surveillance only, thus an estimate of the frequency based on the present number of patient treated with Otrivine Extra Dual Relief cannot be given.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
Overdose of oral or excessive administration of topical xylometazoline hydrochloride may cause severe dizziness, perspiration, severely lowered body temperature, headache, bradycardia, hypertension, respiratory depression, coma and convulsions. Hypertension may be followed by hypotension. Small children are more sensitive to toxicity than adults.
The absorption being very small after nasal or oral administration, an acute overdose after intranasal ipratropium bromide is unlikely but if an overdose occurs the symptoms are dry mouth, accommodation difficulties and tachycardia. The treatment is symptomatic.
A considerable overdose may cause anticholinergic CNS symptoms such as hallucinations, which must be treated with cholinesterase inhibitors.
Appropriate supportive measures should be initiated in all individuals suspected of an overdose, and urgent symptomatic treatment under medical supervision is indicated when warranted. This would include observation of the individual for at least 6 hours. In the event of a severe overdose with cardiac arrest, resuscitation should be continued for at least 1 hour. Further management should be as clinically indicated or as recommended by the national poison centres where available.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
⚠ Not the same combination. This medicine contains Ipratropium bromide, Xylometazoline hydrochloride. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml nasal spray, solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.